Eric Poeschla
Concepts (507)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Immunodeficiency Virus, Feline | 27 | 2023 | 30 | 7.080 |
Why?
| HIV-1 | 38 | 2022 | 768 | 4.960 |
Why?
| Genetic Vectors | 27 | 2013 | 291 | 4.340 |
Why?
| Virus Integration | 20 | 2022 | 68 | 3.060 |
Why?
| Virus Replication | 28 | 2022 | 395 | 2.750 |
Why?
| HIV Integrase | 14 | 2022 | 67 | 2.720 |
Why?
| Intercellular Signaling Peptides and Proteins | 14 | 2022 | 350 | 2.190 |
Why?
| Cats | 24 | 2023 | 193 | 2.140 |
Why?
| RNA, Viral | 11 | 2020 | 566 | 2.110 |
Why?
| Lentiviruses, Primate | 4 | 2023 | 13 | 2.000 |
Why?
| Lentivirus | 12 | 2022 | 45 | 1.970 |
Why?
| Genetic Therapy | 13 | 2013 | 257 | 1.570 |
Why?
| DNA, Viral | 7 | 2022 | 350 | 1.550 |
Why?
| Immunity, Innate | 7 | 2020 | 723 | 1.520 |
Why?
| Cell Line | 34 | 2020 | 2639 | 1.430 |
Why?
| Picornaviridae | 3 | 2020 | 18 | 1.420 |
Why?
| Interferon-Induced Helicase, IFIH1 | 2 | 2020 | 14 | 1.400 |
Why?
| Chromatin | 9 | 2016 | 428 | 1.390 |
Why?
| Reverse Transcription | 4 | 2021 | 18 | 1.200 |
Why?
| Antibodies, Viral | 2 | 2020 | 521 | 1.130 |
Why?
| RNA Interference | 8 | 2020 | 437 | 1.050 |
Why?
| Lentivirus Infections | 4 | 2014 | 7 | 1.040 |
Why?
| Retroviridae | 5 | 2022 | 90 | 1.030 |
Why?
| Gene Transfer Techniques | 10 | 2011 | 147 | 1.000 |
Why?
| Gene Products, gag | 3 | 2012 | 36 | 0.980 |
Why?
| HIV Infections | 15 | 2022 | 2469 | 0.980 |
Why?
| Adaptor Proteins, Signal Transducing | 7 | 2020 | 368 | 0.970 |
Why?
| Integrases | 5 | 2022 | 116 | 0.890 |
Why?
| Virus Assembly | 5 | 2014 | 67 | 0.880 |
Why?
| Trabecular Meshwork | 8 | 2014 | 77 | 0.870 |
Why?
| Interferons | 2 | 2022 | 151 | 0.840 |
Why?
| Animals | 56 | 2023 | 31761 | 0.820 |
Why?
| Capsid | 7 | 2022 | 75 | 0.800 |
Why?
| Transgenes | 8 | 2009 | 170 | 0.790 |
Why?
| Host-Pathogen Interactions | 6 | 2021 | 295 | 0.790 |
Why?
| Aqueous Humor | 6 | 2009 | 31 | 0.780 |
Why?
| Virion | 6 | 2022 | 73 | 0.740 |
Why?
| Spumavirus | 1 | 2020 | 2 | 0.730 |
Why?
| Gammaretrovirus | 1 | 2020 | 2 | 0.730 |
Why?
| Recombinant Fusion Proteins | 6 | 2011 | 617 | 0.710 |
Why?
| Teicoplanin | 1 | 2020 | 17 | 0.690 |
Why?
| Transcription Factors | 7 | 2020 | 1528 | 0.690 |
Why?
| HIV | 6 | 2012 | 208 | 0.690 |
Why?
| Chiroptera | 1 | 2020 | 50 | 0.680 |
Why?
| Antibodies, Neutralizing | 2 | 2022 | 221 | 0.680 |
Why?
| Prisons | 1 | 2020 | 72 | 0.670 |
Why?
| Gram-Positive Bacterial Infections | 1 | 2020 | 61 | 0.660 |
Why?
| Humans | 93 | 2023 | 114716 | 0.660 |
Why?
| Molecular Sequence Data | 17 | 2014 | 2791 | 0.650 |
Why?
| Liver Diseases, Parasitic | 1 | 2019 | 3 | 0.650 |
Why?
| Fascioliasis | 1 | 2019 | 6 | 0.650 |
Why?
| CD4-Positive T-Lymphocytes | 5 | 2014 | 965 | 0.630 |
Why?
| Exodeoxyribonucleases | 1 | 2018 | 24 | 0.620 |
Why?
| Nucleotidyltransferases | 1 | 2018 | 26 | 0.620 |
Why?
| Pneumonia, Viral | 2 | 2020 | 340 | 0.620 |
Why?
| Coronavirus Infections | 2 | 2020 | 332 | 0.620 |
Why?
| Retroviridae Infections | 3 | 2020 | 46 | 0.610 |
Why?
| Amino Acid Sequence | 10 | 2023 | 1988 | 0.600 |
Why?
| Ferrets | 2 | 2020 | 19 | 0.580 |
Why?
| Dyspnea | 1 | 2019 | 213 | 0.570 |
Why?
| Betacoronavirus | 1 | 2020 | 252 | 0.560 |
Why?
| Outpatients | 1 | 2020 | 327 | 0.560 |
Why?
| Eosinophilia | 1 | 2019 | 186 | 0.560 |
Why?
| Transformation, Genetic | 2 | 2012 | 15 | 0.550 |
Why?
| Phosphoproteins | 1 | 2018 | 299 | 0.530 |
Why?
| Antibodies, Monoclonal | 2 | 2020 | 1270 | 0.520 |
Why?
| mRNA Cleavage and Polyadenylation Factors | 4 | 2020 | 26 | 0.510 |
Why?
| Viral Load | 3 | 2020 | 405 | 0.510 |
Why?
| Nuclear Pore Complex Proteins | 2 | 2020 | 31 | 0.500 |
Why?
| Pandemics | 2 | 2020 | 1319 | 0.500 |
Why?
| Gene Knockout Techniques | 2 | 2014 | 99 | 0.480 |
Why?
| DNA, Complementary | 2 | 2013 | 257 | 0.470 |
Why?
| Cat Diseases | 1 | 2014 | 13 | 0.450 |
Why?
| Cytosine Deaminase | 2 | 2010 | 14 | 0.450 |
Why?
| HIV Integrase Inhibitors | 4 | 2022 | 62 | 0.440 |
Why?
| Viral Envelope Proteins | 1 | 2014 | 73 | 0.430 |
Why?
| Transduction, Genetic | 5 | 2008 | 113 | 0.430 |
Why?
| Glaucoma | 2 | 2009 | 202 | 0.430 |
Why?
| Animals, Genetically Modified | 2 | 2011 | 215 | 0.420 |
Why?
| Molecular Chaperones | 1 | 2014 | 157 | 0.420 |
Why?
| Mice | 19 | 2020 | 14916 | 0.400 |
Why?
| RNA-Binding Proteins | 2 | 2014 | 344 | 0.400 |
Why?
| Mutation | 9 | 2020 | 3349 | 0.390 |
Why?
| Lentiviruses, Feline | 1 | 2011 | 1 | 0.390 |
Why?
| Carnivora | 1 | 2011 | 6 | 0.380 |
Why?
| Primate Diseases | 1 | 2011 | 4 | 0.380 |
Why?
| Open Reading Frames | 1 | 2012 | 116 | 0.380 |
Why?
| Antigens, CD | 1 | 2014 | 443 | 0.380 |
Why?
| Monkey Diseases | 1 | 2011 | 19 | 0.380 |
Why?
| Cells, Cultured | 10 | 2012 | 3890 | 0.380 |
Why?
| Nuclear Localization Signals | 3 | 2006 | 14 | 0.380 |
Why?
| Anti-Bacterial Agents | 1 | 2020 | 1477 | 0.370 |
Why?
| Cell Nucleus | 5 | 2021 | 554 | 0.370 |
Why?
| Disease Models, Animal | 5 | 2013 | 3542 | 0.360 |
Why?
| Nerve Tissue Proteins | 1 | 2014 | 529 | 0.360 |
Why?
| Gene Products, vif | 1 | 2010 | 2 | 0.360 |
Why?
| Active Transport, Cell Nucleus | 6 | 2022 | 110 | 0.350 |
Why?
| Cytidine Deaminase | 1 | 2010 | 58 | 0.350 |
Why?
| Intraocular Pressure | 2 | 2009 | 276 | 0.340 |
Why?
| DNA Viruses | 1 | 2009 | 9 | 0.340 |
Why?
| Prostaglandins | 1 | 2009 | 78 | 0.340 |
Why?
| Purines | 1 | 2010 | 159 | 0.330 |
Why?
| Eye Proteins | 4 | 2014 | 71 | 0.330 |
Why?
| Gene Knockdown Techniques | 2 | 2016 | 299 | 0.330 |
Why?
| Gene Expression | 8 | 2013 | 1420 | 0.320 |
Why?
| Green Fluorescent Proteins | 6 | 2011 | 373 | 0.310 |
Why?
| Proteasome Endopeptidase Complex | 2 | 2009 | 134 | 0.310 |
Why?
| Cytoplasm | 5 | 2021 | 255 | 0.300 |
Why?
| Biological Evolution | 1 | 2011 | 416 | 0.300 |
Why?
| Base Sequence | 9 | 2012 | 2118 | 0.300 |
Why?
| Transfection | 5 | 2012 | 870 | 0.290 |
Why?
| Primates | 3 | 2020 | 111 | 0.290 |
Why?
| RNA, Messenger | 4 | 2023 | 2557 | 0.290 |
Why?
| HEK293 Cells | 5 | 2020 | 593 | 0.280 |
Why?
| Retina | 3 | 2004 | 263 | 0.280 |
Why?
| Antiviral Agents | 3 | 2022 | 646 | 0.270 |
Why?
| Mice, Transgenic | 3 | 2020 | 1951 | 0.270 |
Why?
| Gene Targeting | 2 | 2004 | 75 | 0.260 |
Why?
| DNA-(Apurinic or Apyrimidinic Site) Lyase | 1 | 2005 | 2 | 0.260 |
Why?
| Protein Binding | 8 | 2021 | 1896 | 0.260 |
Why?
| Proteins | 3 | 2007 | 912 | 0.250 |
Why?
| Anti-HIV Agents | 2 | 2022 | 666 | 0.250 |
Why?
| HIV-2 | 4 | 2002 | 15 | 0.250 |
Why?
| Oncogenic Viruses | 1 | 2004 | 3 | 0.240 |
Why?
| Genes, Reporter | 4 | 2012 | 257 | 0.240 |
Why?
| HeLa Cells | 7 | 2020 | 562 | 0.240 |
Why?
| Cell Culture Techniques | 3 | 2012 | 343 | 0.230 |
Why?
| Lymphocytes | 4 | 2012 | 332 | 0.230 |
Why?
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2020 | 928 | 0.230 |
Why?
| Pigment Epithelium of Eye | 1 | 2003 | 34 | 0.230 |
Why?
| Acquired Immunodeficiency Syndrome | 2 | 1996 | 218 | 0.220 |
Why?
| Anti-Retroviral Agents | 1 | 2005 | 207 | 0.220 |
Why?
| Evolution, Molecular | 3 | 2020 | 437 | 0.220 |
Why?
| Protein Structure, Tertiary | 5 | 2015 | 797 | 0.220 |
Why?
| Spike Glycoprotein, Coronavirus | 2 | 2022 | 92 | 0.220 |
Why?
| Amino Acids | 2 | 2023 | 448 | 0.220 |
Why?
| Bone Marrow Stromal Antigen 2 | 1 | 2023 | 2 | 0.220 |
Why?
| Human Immunodeficiency Virus Proteins | 1 | 2023 | 6 | 0.220 |
Why?
| Protein Sorting Signals | 1 | 2023 | 16 | 0.220 |
Why?
| Viral Regulatory and Accessory Proteins | 1 | 2023 | 26 | 0.220 |
Why?
| GPI-Linked Proteins | 1 | 2023 | 54 | 0.210 |
Why?
| RNA, Catalytic | 5 | 1998 | 182 | 0.210 |
Why?
| Mutation, Missense | 2 | 2014 | 295 | 0.210 |
Why?
| RNA, Small Interfering | 2 | 2020 | 543 | 0.210 |
Why?
| Cytoskeletal Proteins | 3 | 2008 | 145 | 0.200 |
Why?
| Karyopherins | 2 | 2012 | 15 | 0.200 |
Why?
| Gene Products, env | 3 | 2012 | 7 | 0.200 |
Why?
| Genetic Engineering | 1 | 2003 | 80 | 0.200 |
Why?
| Saliva | 1 | 2023 | 189 | 0.200 |
Why?
| Aotidae | 2 | 2020 | 7 | 0.200 |
Why?
| Virus Cultivation | 2 | 2012 | 25 | 0.200 |
Why?
| Tripartite Motif Proteins | 2 | 2020 | 30 | 0.200 |
Why?
| Promoter Regions, Genetic | 4 | 2012 | 1133 | 0.200 |
Why?
| Cytomegalovirus | 3 | 2012 | 144 | 0.200 |
Why?
| Dogs | 2 | 2014 | 334 | 0.190 |
Why?
| Genome, Viral | 4 | 2019 | 119 | 0.190 |
Why?
| Glycoproteins | 3 | 2008 | 304 | 0.190 |
Why?
| Receptors, Cytoplasmic and Nuclear | 2 | 2012 | 193 | 0.180 |
Why?
| Cyclophilin A | 1 | 2020 | 24 | 0.180 |
Why?
| Drug Resistance, Viral | 2 | 2014 | 99 | 0.180 |
Why?
| 3T3 Cells | 1 | 2020 | 140 | 0.180 |
Why?
| Emigration and Immigration | 1 | 2020 | 44 | 0.180 |
Why?
| Immunologic Surveillance | 1 | 2020 | 19 | 0.180 |
Why?
| Pathogen-Associated Molecular Pattern Molecules | 1 | 2020 | 6 | 0.180 |
Why?
| Receptor, Interferon alpha-beta | 1 | 2020 | 23 | 0.180 |
Why?
| Vesicular Transport Proteins | 1 | 2021 | 83 | 0.180 |
Why?
| Hantavirus Pulmonary Syndrome | 1 | 2020 | 3 | 0.170 |
Why?
| Disease Resistance | 1 | 2020 | 27 | 0.170 |
Why?
| Terminal Repeat Sequences | 1 | 2020 | 15 | 0.170 |
Why?
| Quarantine | 1 | 2020 | 24 | 0.170 |
Why?
| Growth Inhibitors | 2 | 2013 | 43 | 0.170 |
Why?
| Immune Evasion | 1 | 2020 | 47 | 0.170 |
Why?
| Immunoassay | 1 | 2020 | 95 | 0.170 |
Why?
| Endogenous Retroviruses | 1 | 2020 | 19 | 0.170 |
Why?
| Interferon-beta | 1 | 2020 | 79 | 0.170 |
Why?
| RNA Virus Infections | 1 | 2019 | 11 | 0.170 |
Why?
| RNA, Double-Stranded | 1 | 2019 | 44 | 0.170 |
Why?
| Immunoblotting | 2 | 2014 | 283 | 0.170 |
Why?
| RNA Viruses | 1 | 2019 | 28 | 0.170 |
Why?
| Delayed-Action Preparations | 1 | 2020 | 159 | 0.170 |
Why?
| Ciliary Body | 2 | 2009 | 33 | 0.170 |
Why?
| Viremia | 1 | 2020 | 123 | 0.160 |
Why?
| Immunity, Humoral | 1 | 2020 | 112 | 0.160 |
Why?
| Embryonic Development | 1 | 2020 | 117 | 0.160 |
Why?
| Interferon Type I | 1 | 2020 | 128 | 0.160 |
Why?
| Sequence Alignment | 2 | 2014 | 325 | 0.160 |
Why?
| Luminescent Proteins | 3 | 2012 | 165 | 0.160 |
Why?
| Monocytes | 2 | 2018 | 503 | 0.160 |
Why?
| Gene Expression Regulation, Developmental | 2 | 2020 | 799 | 0.160 |
Why?
| Cell Transformation, Viral | 1 | 1998 | 24 | 0.160 |
Why?
| Emigrants and Immigrants | 1 | 2020 | 107 | 0.160 |
Why?
| THP-1 Cells | 1 | 2018 | 19 | 0.160 |
Why?
| Afghanistan | 1 | 2019 | 108 | 0.150 |
Why?
| Residence Characteristics | 1 | 2020 | 275 | 0.150 |
Why?
| Receptors, CXCR4 | 1 | 1998 | 78 | 0.150 |
Why?
| Renal Insufficiency | 1 | 2020 | 136 | 0.150 |
Why?
| T-Lymphocytes | 5 | 2020 | 1745 | 0.150 |
Why?
| Genes, vif | 2 | 2010 | 3 | 0.150 |
Why?
| Rats | 7 | 2014 | 4943 | 0.150 |
Why?
| Protein Transport | 2 | 2012 | 396 | 0.150 |
Why?
| Lupus Erythematosus, Systemic | 1 | 2020 | 221 | 0.140 |
Why?
| Viral Proteins | 2 | 2015 | 281 | 0.140 |
Why?
| TOR Serine-Threonine Kinases | 1 | 2020 | 359 | 0.140 |
Why?
| Genes, Immediate-Early | 2 | 2012 | 15 | 0.140 |
Why?
| Quinolines | 2 | 2014 | 129 | 0.140 |
Why?
| High-Throughput Nucleotide Sequencing | 1 | 2019 | 440 | 0.140 |
Why?
| Public Health | 1 | 2020 | 434 | 0.130 |
Why?
| Kinetics | 6 | 2013 | 1550 | 0.130 |
Why?
| Plasmids | 4 | 2012 | 345 | 0.130 |
Why?
| Genes, Viral | 1 | 2015 | 89 | 0.130 |
Why?
| Female | 15 | 2020 | 59486 | 0.130 |
Why?
| Epigenesis, Genetic | 1 | 2020 | 521 | 0.130 |
Why?
| Blotting, Western | 5 | 2015 | 1151 | 0.120 |
Why?
| Healthcare Disparities | 1 | 2020 | 479 | 0.120 |
Why?
| Species Specificity | 2 | 2012 | 545 | 0.120 |
Why?
| Transcription, Genetic | 3 | 2016 | 1316 | 0.120 |
Why?
| Echinocandins | 1 | 2014 | 8 | 0.120 |
Why?
| Gene Expression Regulation | 1 | 2003 | 2321 | 0.120 |
Why?
| rhoA GTP-Binding Protein | 1 | 2014 | 73 | 0.120 |
Why?
| Gene Products, rev | 2 | 2004 | 5 | 0.120 |
Why?
| Mucormycosis | 1 | 2014 | 20 | 0.120 |
Why?
| Amphotericin B | 1 | 2014 | 29 | 0.120 |
Why?
| beta-Galactosidase | 2 | 2004 | 62 | 0.120 |
Why?
| Voriconazole | 1 | 2014 | 24 | 0.120 |
Why?
| Acetates | 1 | 2014 | 95 | 0.120 |
Why?
| Polymerase Chain Reaction | 2 | 2014 | 994 | 0.110 |
Why?
| Ocular Hypertension | 1 | 2014 | 61 | 0.110 |
Why?
| Cyclophilins | 1 | 2014 | 29 | 0.110 |
Why?
| Antifungal Agents | 1 | 2014 | 128 | 0.110 |
Why?
| Rats, Sprague-Dawley | 4 | 2014 | 2209 | 0.110 |
Why?
| Introns | 3 | 2015 | 227 | 0.110 |
Why?
| Mice, Knockout | 3 | 2015 | 2582 | 0.110 |
Why?
| Retroviridae Proteins | 2 | 2012 | 11 | 0.110 |
Why?
| Mice, Inbred C57BL | 2 | 2020 | 4710 | 0.110 |
Why?
| Protein Multimerization | 1 | 2014 | 159 | 0.110 |
Why?
| DNA-Binding Proteins | 3 | 2013 | 1314 | 0.110 |
Why?
| Vero Cells | 2 | 2019 | 63 | 0.100 |
Why?
| F-Box Proteins | 1 | 2012 | 20 | 0.100 |
Why?
| gag Gene Products, Human Immunodeficiency Virus | 1 | 2012 | 12 | 0.100 |
Why?
| Collagen | 1 | 2014 | 415 | 0.100 |
Why?
| Genes, env | 1 | 2012 | 4 | 0.100 |
Why?
| Male | 12 | 2020 | 55558 | 0.100 |
Why?
| Genes, Synthetic | 1 | 2012 | 14 | 0.100 |
Why?
| Mink | 1 | 2011 | 12 | 0.100 |
Why?
| Antigens, Neoplasm | 1 | 2013 | 222 | 0.100 |
Why?
| Rabbits | 2 | 2011 | 736 | 0.100 |
Why?
| Feline Acquired Immunodeficiency Syndrome | 1 | 2011 | 1 | 0.100 |
Why?
| Macrophages | 3 | 2009 | 1261 | 0.100 |
Why?
| DNA | 3 | 2005 | 1351 | 0.100 |
Why?
| bcl-2 Homologous Antagonist-Killer Protein | 1 | 2011 | 13 | 0.100 |
Why?
| Signal Transduction | 2 | 2020 | 4521 | 0.100 |
Why?
| Caspase 8 | 1 | 2011 | 43 | 0.100 |
Why?
| bcl-2-Associated X Protein | 1 | 2011 | 45 | 0.090 |
Why?
| Histidine | 2 | 2014 | 57 | 0.090 |
Why?
| Jurkat Cells | 3 | 2020 | 128 | 0.090 |
Why?
| APOBEC-3G Deaminase | 1 | 2010 | 6 | 0.090 |
Why?
| vif Gene Products, Human Immunodeficiency Virus | 1 | 2010 | 4 | 0.090 |
Why?
| Injections | 2 | 2009 | 159 | 0.090 |
Why?
| Young Adult | 4 | 2020 | 10462 | 0.090 |
Why?
| Neoplasms | 2 | 2013 | 2105 | 0.090 |
Why?
| Virus Internalization | 1 | 2010 | 40 | 0.090 |
Why?
| Polyradiculoneuropathy | 1 | 2009 | 3 | 0.090 |
Why?
| Swine | 2 | 2009 | 700 | 0.080 |
Why?
| Autoimmune Diseases of the Nervous System | 1 | 2009 | 21 | 0.080 |
Why?
| Isoenzymes | 1 | 2010 | 285 | 0.080 |
Why?
| Protein Processing, Post-Translational | 2 | 2004 | 399 | 0.080 |
Why?
| United States | 3 | 2020 | 12176 | 0.080 |
Why?
| Iris | 1 | 2009 | 19 | 0.080 |
Why?
| Saccharomyces cerevisiae | 1 | 2013 | 477 | 0.080 |
Why?
| Macaca fascicularis | 1 | 2009 | 51 | 0.080 |
Why?
| Endosomes | 1 | 2010 | 124 | 0.080 |
Why?
| Cyclooxygenase 2 | 1 | 2009 | 164 | 0.080 |
Why?
| Intracellular Fluid | 1 | 2008 | 27 | 0.080 |
Why?
| Recombinant Proteins | 2 | 2009 | 1233 | 0.080 |
Why?
| Antigens, Viral | 1 | 2009 | 176 | 0.080 |
Why?
| Cell Division | 2 | 2001 | 759 | 0.080 |
Why?
| Ubiquitin-Protein Ligases | 2 | 2007 | 139 | 0.080 |
Why?
| Infectious Anemia Virus, Equine | 1 | 2007 | 1 | 0.080 |
Why?
| Occupational Diseases | 1 | 2009 | 128 | 0.080 |
Why?
| rev Gene Products, Human Immunodeficiency Virus | 2 | 2004 | 5 | 0.070 |
Why?
| Phylogeny | 1 | 2011 | 794 | 0.070 |
Why?
| Cell Membrane | 3 | 2010 | 679 | 0.070 |
Why?
| Glaucoma, Open-Angle | 1 | 2009 | 95 | 0.070 |
Why?
| Leukocytes, Mononuclear | 1 | 2010 | 493 | 0.070 |
Why?
| Antigens, CD34 | 2 | 1998 | 89 | 0.070 |
Why?
| Gene Products, pol | 2 | 1998 | 6 | 0.070 |
Why?
| Models, Genetic | 1 | 2009 | 565 | 0.070 |
Why?
| Virulence | 1 | 2007 | 227 | 0.070 |
Why?
| Occupational Exposure | 1 | 2009 | 255 | 0.070 |
Why?
| Crystallography, X-Ray | 2 | 2020 | 405 | 0.070 |
Why?
| Binding Sites | 2 | 2021 | 1176 | 0.070 |
Why?
| Time Factors | 2 | 2009 | 6124 | 0.070 |
Why?
| Oxidative Stress | 1 | 2012 | 1084 | 0.070 |
Why?
| Chromosomes, Human | 1 | 2006 | 39 | 0.070 |
Why?
| Retinal Ganglion Cells | 2 | 2004 | 92 | 0.070 |
Why?
| Image Processing, Computer-Assisted | 1 | 2010 | 683 | 0.060 |
Why?
| Models, Biological | 1 | 2013 | 1630 | 0.060 |
Why?
| Mitochondria | 1 | 2011 | 751 | 0.060 |
Why?
| Sequence Deletion | 1 | 2006 | 167 | 0.060 |
Why?
| Organ Culture Techniques | 2 | 2006 | 141 | 0.060 |
Why?
| Cell Survival | 1 | 2009 | 1021 | 0.060 |
Why?
| Avian Leukosis Virus | 1 | 2005 | 6 | 0.060 |
Why?
| Peptide Fragments | 1 | 2009 | 668 | 0.060 |
Why?
| Genes, Regulator | 1 | 2005 | 34 | 0.060 |
Why?
| Protein Structure, Secondary | 1 | 2006 | 325 | 0.060 |
Why?
| Leukemia Virus, Gibbon Ape | 1 | 2005 | 1 | 0.060 |
Why?
| Nuclear Proteins | 1 | 2009 | 592 | 0.060 |
Why?
| Genes, gag | 1 | 2004 | 3 | 0.060 |
Why?
| NIH 3T3 Cells | 1 | 2005 | 137 | 0.060 |
Why?
| Proteasome Inhibitors | 1 | 2004 | 40 | 0.060 |
Why?
| Ribonucleases | 1 | 2004 | 52 | 0.060 |
Why?
| Antiretroviral Therapy, Highly Active | 1 | 2006 | 256 | 0.060 |
Why?
| Histones | 1 | 2009 | 536 | 0.060 |
Why?
| Ubiquitin | 1 | 2004 | 57 | 0.060 |
Why?
| Hematopoietic Stem Cells | 2 | 1998 | 345 | 0.060 |
Why?
| Indicators and Reagents | 1 | 2004 | 99 | 0.060 |
Why?
| Genetic Predisposition to Disease | 1 | 2012 | 2099 | 0.060 |
Why?
| Genes, vpu | 1 | 2004 | 1 | 0.060 |
Why?
| Immunoprecipitation | 1 | 2004 | 152 | 0.060 |
Why?
| Models, Molecular | 2 | 2022 | 1378 | 0.060 |
Why?
| Protease Inhibitors | 1 | 2004 | 97 | 0.060 |
Why?
| Alleles | 2 | 2020 | 791 | 0.060 |
Why?
| Digestive System Diseases | 1 | 2003 | 23 | 0.060 |
Why?
| Carrier Proteins | 1 | 2007 | 696 | 0.060 |
Why?
| Gene Expression Regulation, Viral | 1 | 2004 | 80 | 0.050 |
Why?
| Microscopy, Confocal | 1 | 2004 | 305 | 0.050 |
Why?
| Adenoviridae | 1 | 2004 | 185 | 0.050 |
Why?
| Microscopy, Fluorescence | 1 | 2004 | 398 | 0.050 |
Why?
| Gene Expression Regulation, Enzymologic | 1 | 2004 | 271 | 0.050 |
Why?
| Virus Uncoating | 1 | 2022 | 1 | 0.050 |
Why?
| Eye Diseases | 1 | 2003 | 76 | 0.050 |
Why?
| Cell Cycle | 1 | 2005 | 543 | 0.050 |
Why?
| Apoptosis | 1 | 2011 | 2369 | 0.050 |
Why?
| Middle Aged | 6 | 2020 | 26746 | 0.050 |
Why?
| Respiratory Tract Diseases | 1 | 2003 | 139 | 0.050 |
Why?
| Aphidicolin | 1 | 2001 | 6 | 0.050 |
Why?
| Capsid Proteins | 1 | 2022 | 69 | 0.050 |
Why?
| Leukemia Virus, Murine | 1 | 2001 | 16 | 0.050 |
Why?
| Lac Operon | 1 | 2001 | 44 | 0.050 |
Why?
| Catalytic Domain | 1 | 2022 | 197 | 0.050 |
Why?
| Breast Neoplasms | 1 | 2012 | 1868 | 0.050 |
Why?
| Nuclear Pore | 1 | 2021 | 14 | 0.050 |
Why?
| Osteoblasts | 1 | 2002 | 106 | 0.050 |
Why?
| Organ Specificity | 1 | 2001 | 268 | 0.050 |
Why?
| Acute Disease | 1 | 2023 | 912 | 0.050 |
Why?
| Deuterium Exchange Measurement | 1 | 2020 | 29 | 0.050 |
Why?
| Nervous System Diseases | 1 | 2003 | 252 | 0.050 |
Why?
| Amino Acid Motifs | 1 | 2021 | 198 | 0.040 |
Why?
| Neurons | 2 | 1998 | 1280 | 0.040 |
Why?
| Horses | 1 | 2020 | 96 | 0.040 |
Why?
| Macaca mulatta | 1 | 2020 | 131 | 0.040 |
Why?
| Nuclear Respiratory Factor 1 | 1 | 2020 | 3 | 0.040 |
Why?
| DNA (Cytosine-5-)-Methyltransferase 1 | 1 | 2020 | 13 | 0.040 |
Why?
| HCT116 Cells | 1 | 2020 | 71 | 0.040 |
Why?
| Cryoelectron Microscopy | 1 | 2020 | 144 | 0.040 |
Why?
| Structure-Activity Relationship | 1 | 2021 | 503 | 0.040 |
Why?
| Proteinuria | 1 | 2020 | 77 | 0.040 |
Why?
| Travel | 1 | 2020 | 121 | 0.040 |
Why?
| Sheep | 1 | 2022 | 764 | 0.040 |
Why?
| Protein Domains | 1 | 2020 | 207 | 0.040 |
Why?
| Immunohistochemistry | 2 | 2015 | 1635 | 0.040 |
Why?
| Needs Assessment | 1 | 2020 | 313 | 0.040 |
Why?
| Aged | 4 | 2020 | 19079 | 0.040 |
Why?
| Giant Cells | 1 | 1998 | 21 | 0.040 |
Why?
| Health Status Disparities | 1 | 2020 | 201 | 0.040 |
Why?
| Rodentia | 1 | 1998 | 44 | 0.040 |
Why?
| Brain | 1 | 2009 | 2369 | 0.040 |
Why?
| RNA-Directed DNA Polymerase | 1 | 1998 | 34 | 0.040 |
Why?
| Drug Therapy, Combination | 2 | 2014 | 954 | 0.040 |
Why?
| Coculture Techniques | 1 | 1998 | 201 | 0.040 |
Why?
| Cattle | 1 | 2020 | 921 | 0.040 |
Why?
| Mutagenesis | 1 | 1998 | 170 | 0.040 |
Why?
| Repetitive Sequences, Nucleic Acid | 1 | 1998 | 104 | 0.040 |
Why?
| Gene Deletion | 1 | 1998 | 356 | 0.030 |
Why?
| Age Factors | 1 | 2003 | 2889 | 0.030 |
Why?
| RNA | 1 | 2022 | 810 | 0.030 |
Why?
| Receptors, Antigen, T-Cell | 1 | 2020 | 618 | 0.030 |
Why?
| Diagnosis, Differential | 1 | 2020 | 1340 | 0.030 |
Why?
| DNA Methylation | 1 | 2020 | 496 | 0.030 |
Why?
| Cell Line, Tumor | 2 | 2013 | 2725 | 0.030 |
Why?
| In Situ Hybridization | 1 | 2015 | 293 | 0.030 |
Why?
| AIDS Vaccines | 1 | 1995 | 41 | 0.030 |
Why?
| Mutant Proteins | 1 | 2014 | 95 | 0.030 |
Why?
| Receptors, Purinergic | 3 | 1990 | 20 | 0.030 |
Why?
| RNA Splicing | 1 | 2015 | 245 | 0.030 |
Why?
| Real-Time Polymerase Chain Reaction | 1 | 2015 | 316 | 0.030 |
Why?
| Amino Acid Substitution | 1 | 2014 | 262 | 0.030 |
Why?
| History, 21st Century | 1 | 2014 | 160 | 0.030 |
Why?
| Vesicular stomatitis Indiana virus | 1 | 2013 | 13 | 0.030 |
Why?
| Biomarkers | 1 | 2023 | 3414 | 0.030 |
Why?
| Oligonucleotide Array Sequence Analysis | 1 | 2015 | 743 | 0.030 |
Why?
| Virus Diseases | 1 | 2015 | 195 | 0.030 |
Why?
| Enzyme-Linked Immunosorbent Assay | 1 | 2015 | 797 | 0.030 |
Why?
| Topoisomerase II Inhibitors | 1 | 2013 | 23 | 0.030 |
Why?
| Fungi | 1 | 2014 | 124 | 0.030 |
Why?
| DNA Topoisomerases, Type II | 1 | 2013 | 44 | 0.030 |
Why?
| Galactose | 1 | 2013 | 20 | 0.030 |
Why?
| Tumor Escape | 1 | 2013 | 36 | 0.030 |
Why?
| Gene Library | 1 | 2013 | 114 | 0.030 |
Why?
| L-Lactate Dehydrogenase | 1 | 2013 | 107 | 0.030 |
Why?
| Succinate Dehydrogenase | 1 | 2013 | 42 | 0.030 |
Why?
| Immunotherapy, Adoptive | 1 | 1995 | 184 | 0.030 |
Why?
| Immunotherapy | 2 | 2013 | 475 | 0.030 |
Why?
| Sequence Homology, Nucleic Acid | 1 | 2012 | 152 | 0.030 |
Why?
| Antibiotics, Antineoplastic | 1 | 2013 | 109 | 0.030 |
Why?
| Serine-Arginine Splicing Factors | 1 | 2012 | 18 | 0.030 |
Why?
| Drug Evaluation, Preclinical | 1 | 2013 | 165 | 0.030 |
Why?
| Receptors, Cell Surface | 2 | 1984 | 354 | 0.030 |
Why?
| Cardiovascular Diseases | 1 | 2003 | 1727 | 0.030 |
Why?
| Molecular Conformation | 1 | 2012 | 138 | 0.030 |
Why?
| Paraganglioma | 1 | 2013 | 47 | 0.030 |
Why?
| Doxorubicin | 1 | 2013 | 286 | 0.020 |
Why?
| Protein Conformation | 1 | 2014 | 811 | 0.020 |
Why?
| Risk Assessment | 1 | 2020 | 2973 | 0.020 |
Why?
| DNA Primers | 1 | 2012 | 514 | 0.020 |
Why?
| Caspase 9 | 1 | 2011 | 48 | 0.020 |
Why?
| Epitopes | 1 | 2013 | 435 | 0.020 |
Why?
| Microscopy, Electron | 1 | 2011 | 410 | 0.020 |
Why?
| Adenosine | 2 | 1990 | 202 | 0.020 |
Why?
| Adipose Tissue | 2 | 1984 | 539 | 0.020 |
Why?
| Salt Gland | 1 | 1990 | 1 | 0.020 |
Why?
| Clinical Trials as Topic | 1 | 1995 | 934 | 0.020 |
Why?
| Recurrence | 1 | 2013 | 936 | 0.020 |
Why?
| Colorado | 1 | 2020 | 4086 | 0.020 |
Why?
| Abattoirs | 1 | 2009 | 2 | 0.020 |
Why?
| Indiana | 1 | 2009 | 27 | 0.020 |
Why?
| Myelin Basic Protein | 1 | 2009 | 45 | 0.020 |
Why?
| Adult | 3 | 2020 | 30543 | 0.020 |
Why?
| Air Pollutants, Occupational | 1 | 2009 | 27 | 0.020 |
Why?
| Enzyme Inhibitors | 1 | 2013 | 751 | 0.020 |
Why?
| Chlorides | 1 | 1990 | 127 | 0.020 |
Why?
| Cyclic AMP | 1 | 1990 | 225 | 0.020 |
Why?
| Repressor Proteins | 1 | 2012 | 367 | 0.020 |
Why?
| Minnesota | 1 | 2009 | 134 | 0.020 |
Why?
| Models, Theoretical | 1 | 2013 | 516 | 0.020 |
Why?
| Demyelinating Diseases | 1 | 2009 | 75 | 0.020 |
Why?
| Inhalation Exposure | 1 | 2009 | 97 | 0.020 |
Why?
| Drug Resistance, Neoplasm | 1 | 2013 | 642 | 0.020 |
Why?
| Aerosols | 1 | 2009 | 151 | 0.020 |
Why?
| Cell Cycle Proteins | 1 | 2012 | 552 | 0.020 |
Why?
| Binding Sites, Antibody | 1 | 2008 | 36 | 0.020 |
Why?
| Follow-Up Studies | 2 | 2009 | 4420 | 0.020 |
Why?
| Culture Media, Conditioned | 1 | 2008 | 105 | 0.020 |
Why?
| Hybridomas | 1 | 2008 | 230 | 0.020 |
Why?
| Antibody Specificity | 1 | 2008 | 176 | 0.020 |
Why?
| Consensus Sequence | 1 | 2007 | 70 | 0.020 |
Why?
| Flow Cytometry | 1 | 2011 | 1086 | 0.020 |
Why?
| Eye | 1 | 2008 | 101 | 0.020 |
Why?
| Disease Outbreaks | 1 | 2009 | 309 | 0.020 |
Why?
| Melanoma | 1 | 2013 | 629 | 0.020 |
Why?
| Drug Resistance, Multiple, Viral | 1 | 2006 | 11 | 0.020 |
Why?
| Prostatic Neoplasms | 1 | 2013 | 925 | 0.020 |
Why?
| Aged, 80 and over | 2 | 2008 | 6346 | 0.020 |
Why?
| HIV Protease Inhibitors | 1 | 2006 | 64 | 0.020 |
Why?
| Microarray Analysis | 1 | 2005 | 119 | 0.020 |
Why?
| Mice, Inbred BALB C | 1 | 2008 | 1151 | 0.020 |
Why?
| Phenotype | 1 | 2013 | 2811 | 0.020 |
Why?
| Treatment Failure | 1 | 2006 | 332 | 0.020 |
Why?
| Clinical Protocols | 2 | 1998 | 232 | 0.020 |
Why?
| Gene Silencing | 1 | 2005 | 172 | 0.020 |
Why?
| Ethylmaleimide | 1 | 1984 | 18 | 0.020 |
Why?
| Guanine Nucleotides | 1 | 1984 | 15 | 0.010 |
Why?
| Defective Viruses | 1 | 2004 | 4 | 0.010 |
Why?
| Codon | 1 | 2004 | 86 | 0.010 |
Why?
| PHEX Phosphate Regulating Neutral Endopeptidase | 1 | 2002 | 1 | 0.010 |
Why?
| Hypophosphatemia, Familial | 1 | 2002 | 3 | 0.010 |
Why?
| Autoantibodies | 1 | 2009 | 1350 | 0.010 |
Why?
| Dose-Response Relationship, Drug | 1 | 2006 | 1846 | 0.010 |
Why?
| Photoreceptor Cells, Vertebrate | 1 | 2002 | 25 | 0.010 |
Why?
| Adolescent | 1 | 2020 | 17808 | 0.010 |
Why?
| Golgi Apparatus | 1 | 2002 | 89 | 0.010 |
Why?
| Growth Plate | 1 | 2002 | 32 | 0.010 |
Why?
| Blood Platelets | 1 | 1984 | 351 | 0.010 |
Why?
| Vitreous Body | 1 | 2002 | 101 | 0.010 |
Why?
| Mice, Inbred Strains | 1 | 2002 | 396 | 0.010 |
Why?
| Skull | 1 | 2002 | 119 | 0.010 |
Why?
| In Vitro Techniques | 3 | 1990 | 1013 | 0.010 |
Why?
| Endoplasmic Reticulum | 1 | 2002 | 234 | 0.010 |
Why?
| Animals, Newborn | 1 | 2002 | 777 | 0.010 |
Why?
| Lymphocyte Transfusion | 1 | 1998 | 19 | 0.010 |
Why?
| Clinical Trials, Phase I as Topic | 1 | 1998 | 46 | 0.010 |
Why?
| Adenylyl Cyclases | 2 | 1990 | 82 | 0.010 |
Why?
| Skin | 1 | 2002 | 659 | 0.010 |
Why?
| Phenylisopropyladenosine | 2 | 1984 | 5 | 0.010 |
Why?
| Hydrolysis | 1 | 1995 | 175 | 0.010 |
Why?
| RNA Polymerase III | 1 | 1994 | 25 | 0.010 |
Why?
| Gentamicins | 1 | 1994 | 42 | 0.010 |
Why?
| RNA, Antisense | 1 | 1994 | 17 | 0.010 |
Why?
| Drug Resistance | 1 | 1994 | 158 | 0.010 |
Why?
| Treatment Outcome | 1 | 2006 | 9089 | 0.010 |
Why?
| Selection, Genetic | 1 | 1994 | 243 | 0.010 |
Why?
| 2-Chloroadenosine | 1 | 1990 | 3 | 0.010 |
Why?
| Dogfish | 1 | 1990 | 4 | 0.010 |
Why?
| Colforsin | 1 | 1990 | 44 | 0.010 |
Why?
| Somatostatin | 1 | 1990 | 52 | 0.010 |
Why?
| Theophylline | 1 | 1990 | 60 | 0.010 |
Why?
| Perfusion | 1 | 1990 | 145 | 0.010 |
Why?
| Hematopoietic Stem Cell Transplantation | 1 | 1994 | 524 | 0.000 |
Why?
| Adenosine-5'-(N-ethylcarboxamide) | 1 | 1984 | 9 | 0.000 |
Why?
| Xanthines | 1 | 1984 | 15 | 0.000 |
Why?
| Tritium | 1 | 1984 | 66 | 0.000 |
Why?
| Radioligand Assay | 1 | 1984 | 43 | 0.000 |
Why?
| Guanosine Triphosphate | 1 | 1984 | 85 | 0.000 |
Why?
| Magnesium | 1 | 1984 | 145 | 0.000 |
Why?
| Sodium | 1 | 1984 | 182 | 0.000 |
Why?
| Vasodilator Agents | 1 | 1984 | 303 | 0.000 |
Why?
| Calcium | 1 | 1984 | 1103 | 0.000 |
Why?
|
|
Poeschla's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|